Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Breast Cancer Test will Help More Women Avoid Unnecessary Chemotherapy

Published: Friday, July 05, 2013
Last Updated: Friday, July 05, 2013
Bookmark and Share
A new genetic test will help doctors better identify those women who should be considered for chemotherapy, and those who can avoid it.

A team at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Queen Mary University of London found that the test - called PAM50 - produced better long-term information than current methods for determining if a patient’s breast cancer would return.

The test, which can be processed locally instead of being sent off to an American lab, indentifies more women with the highest risk of their breast cancer returning, with fewer women classed as at intermediate risk.

The new test could therefore help doctors identify with greater certainty the women who will have the most potential of benefitting from chemotherapy, while letting others avoid unnecessary treatment.

The research, published today (Monday) in the Journal of Clinical Oncology, was funded by Breakthrough Breast Cancer, AstraZeneca and the NIHR Biomedical Research Centre at The Royal Marsden, with additional support from Cancer Research UK.

Breast cancer is diagnosed in 50,000 women every year, with 80% of cases caused by oestrogen receptor positive (ER+) disease. Women with this type of breast cancer can be treated with hormone therapy, but for some women, the risk of their breast cancer coming back within 10 years means they are also given chemotherapy.

Currently, a test called Oncotype DX (1) can assess the likelihood of a patient’s breast cancer returning, but the test costs more than £2,000 per patient to be administered privately and samples must be sent abroad to be processed. The current test also identifies a large portion of women as having ‘intermediate risk’, making a doctor’s decision of whether chemotherapy will help more difficult.

In this study, scientists assessed RNA in tissue samples taken from 940 patients with ER+ breast cancer and compared the new PAM50 score, which analyses 50 genes linked with breast cancer, with the Oncotype DX test, and with a test called IHC4, developed by Breakthrough Breast Cancer.

The PAM50 test provided more long-term predictive information for doctors than both the Oncotype DX test and IHC4, while being as effective as other tests in identifying women at low risk of their breast cancer recurring.

Notably, the PAM50 test categorised more patients as having a high risk of their breast cancer returning within 10 years and fewer as intermediate than the other two tests. The researchers said the PAM50 test could therefore be a more cost-effective tool while providing doctors with more relevant information for determining which breast cancer patients will benefit most from chemotherapy.

Professor Mitch Dowsett, Professor of Biochemical Endocrinology at The Institute of Cancer Research and Head of Biochemistry at The Royal Marsden, said: “Chemotherapy is often used after surgery to reduce the risk of a patient’s breast cancer coming back, but the side-effects are significant and some women will not see any benefit. While the current test is useful for both patients and clinicians to help them decide whether chemotherapy is needed, it’s expensive and not available locally.

“Our study found that the PAM50 test is more effective than other methods at providing the information to exclude breast cancer patients from unnecessary chemotherapy, and has the potential to be done more quickly. For each sub-group of breast cancer the PAM50 test added significant information beyond that of the standard clinical treatment score and the Oncotype DX score combined.”

Professor Alan Ashworth, Chief Executive of The Institute of Cancer Research, said: “The great strides that have been made in breast cancer treatment have resulted in a large rise in survival from the disease, but some women receive treatment which can be arduous while receiving no benefit. This test will improve doctors’ knowledge of who might benefit, allowing more women to make better informed decisions on their treatment.”

Breakthrough Breast Cancer’s Director of Research Julia Wilson said: “The PAM50 test has been proven to be an effective way of helping clinicians ensure that women do not have to undergo chemotherapy treatment that will not have any medical benefit, when their risk of cancer recurrence is in fact very low. This will mean that, where appropriate, women will be able to avoid the toxic side effects of chemotherapy.

“We’re aiming to reach a stage where all breast cancer patients receive the  most appropriate treatment for them, and this research from Mitch and his team is an important step in that direction.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

‘Ecologically Diverse’ Breast Cancers More Likely to be Deadly
Breast cancers which are particularly complex and diverse, as judged by a test used in ecology to analyse species of animals and plants, are particularly likely to progress and lead to death, a new study shows.
Thursday, February 18, 2016
Nuevolution Enter Drug Discovery Collaboration with ICR and CRT
International deal to screen potential cancer drugs using DNA ‘barcodes’.
Thursday, January 23, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!